Nano Drug Delivery

Published April 2005

This report examines the business opportunities that are being created by nano-engineered solutions for the drug delivery market. According to one source, approximately $65 billion in drug revenues every year are accounted for by pharmaceuticals with poor bio-availability which far too often results in higher patient costs and inefficient treatment but also, more importantly, increased risks of toxicity or even death.

Because nanotechnology focuses on the very small it is uniquely suited to creating systems that can better deliver drugs to tiny areas within the body. Nano-enabled drug delivery also makes it possible for drugs to permeate through cell walls, which is of critical importance to the expected growth of genetic medicine over the next few years.

Key Reasons to Purchase

- Identifies and quantifies current and future market opportunities - This report examines the business prospects for new delivery materials and methods, tools, and end-use applications being enabled by developments in nanotechnology.

- Identifies key issues in the commercialization process - Chapter Three of this report covers several areas of concern in bringing nano-enabled drug delivery products to market. This includes information on the general business climate for startups and big pharma, fundraising strategies and caveats, how companies are shaping the intellectual property landscape, potential litigation issues, and possible exit scenarios for investors in related companies.

- Defines current and future applications for nanotechnology in drug delivery It is widely perceived that the nanotechnology will have a profound effect on the pharmaceutical industry. Emerging nanotechnology tools and techniques are expected to reduce the required time and cost to bring a new drug delivery platform to-market. Nanotech-enabled drugs are beginning to fill the drug R&D pipeline, and perhaps extend the useful life of existing drugs. This report aims to highlight the major nano-enabled drug delivery technologies that are commercially available or under development.

- Analyzes the efforts of companies in nano-enabled drug delivery - Much of the difficulty in commercializing new technologies lies in execution. While most startups claim promising research with early human or animal clinical results, many will be unable to secure a profitable niche in the industry. NanoMarkets will comment on various collaborations, strategic alliances and/or partnerships with pharmaceutical companies, academic research institutions and biotechnology companies. We believe that such partnerships are vital for the success of nano-enabled drug delivery companies.

- Evaluates funding mechanisms for nanotechnology in the pharmaceutical environment - There are several sources of capital available for R&D, including traditional and corporate venture capital, debt financing, sponsored research and non-recurring engineering funds, federal & state grants, etc. Several government initiatives are in place that vary widely from region to region. This report addresses some of the regulatory issues and funding policies that are affecting the growth of nanotechnology and nano-enabled drug delivery on a global scale.

- Forecasts the market for new technologies broken out by drug delivery type and technology platform - Areas covered include encapsulation technologies, implantable delivery methods, imaging agents and microneedles. Technologies covered include dendrimers, nanotubes and fullerenes, nanoparticles, quantum dots and magnetic/electrical targeting methods.

Target Audience

This unique report will be of vital interest to drug delivery system manufacturers, other medical device manufacturers, pharmaceutical and biotech firms and healthcare providers. The report should also be of interest to financial industry professionals working in equity analysis, venture capital, investment banking and private equity firms.

Further Information: http://www.marketreports.com/x1433.html